# Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

> **NCT00248560** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 36 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00248560
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2009-12
- **Final completion:** 2012-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248560, "Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00248560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*